In This Article:
Nebius Group (NBIS) shares are rising after Bezos Expeditions invested $72 million into AI services developer Toloka, which is owned by Nebius.
Oscar Health (OSCR) surges by over 20% on Wednesday morning after the insurance provider beat first quarter earnings and revenue estimates. Catch Finance's interview with Oscar Health (OSCR) CEO Mark Bertolini from December 2024, where he characterized the healthcare system as having been "broken for some time."
Sarepta Therapeutics (SRPT) shares, on the other hand, are tumbling after cutting its full-year outlook.
To watch more expert insights and analysis on the latest market action, check out more Wealth here.
Now, time for some of today's trending tickers. We are watching Nebius Group, Oscar Health and Sarepta. First up, AI infrastructure company Nebius Group, rising on a multimillion dollar investment. Reuters reports, the Jeff Bezos led Bezos Expeditions, leading a $72 million investment in AI solutions company Toloka, which is part of the Nasdaq listed Nebius Group. Toloka helps train AI models and has worked with Amazon, Microsoft and Anthropic. The CEO of Toloka says, the milestone investment should accelerate the company's growth. Additionally, the CTO of Shopify is participating as well in the investment and will join Toloka's board as executive chairman. Next up, Oscar Health shares are skyrocketing on its first quarter earnings print. The health insurer reporting adjusted EBITDA of $328.8 million, beating the nearly $281 million estimate and the revenue also came in above expectations, increasing 42% from the year prior, which the company attributes to higher membership. Oscar Health reaffirming its full year outlook. Finally, Sarepta shares falling after the drug maker cut its net product revenues forecast for the full year. The firm now sees revenues of $2.3 billion to $2.6 billion. It previously saw $2.9 billion to $3.1 billion, and it comes after disappointing product sales in the first quarter. Analysts see this adding to existing pressures, which include a recent patient death and a change in FDA leadership.
